---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-193927"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:09:36.565499+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Lexeo appoints Dr. Laura Sepp-Lorenzino to board and Science & Technology Committee

## Summary
- Dr. Sepp-Lorenzino appointed April 28, 2026; term expires at 2028 annual meeting.
- She joins Science & Technology Committee; prior CSO of Intellia Therapeutics (2019-2025).
- Compensation: $40k annual cash, initial option for 50,000 shares; first annual grant in 2027.
- Previously held leadership roles at Vertex, Alnylam, and Merck in RNA therapeutics/oncology.

## SEC filing metadata
- accession: 0001193125-26-193927
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312526193927/0001193125-26-193927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312526193927/lxeo-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-193927
- JSON: https://secwatch.observer/filing/0001193125-26-193927.json
- Plain text: https://secwatch.observer/filing/0001193125-26-193927.txt

## Key facts
- Executive change
  Dr. Laura Sepp-Lorenzino was appointed as Director at Lexeo Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On April 28, 2026 (the “ Appointment Date ”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “ Board ”) of Lexeo Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000119312526193927/0001193125-26-193927-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.